Sanofi multiple myeloma treatment gets FDA orphan drug status
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an investigational therapy being developed by Sanofi for people with…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreThe U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an investigational therapy being developed by Sanofi for people with…
During my mom’s last support group meeting, the facilitator asked all the participants to introduce themselves and identify their cancer by name. One after the…
Johnson & Johnson‘s Darzalex (daratumumab) is now the first approved treatment for high-risk smoldering multiple myeloma (SMM) in the European Union (EU). SMM…
“You are very strong.” People say this as if it’s a compliment. Sometimes when I hear it, I smile back at them and mutter, “Thank…
Two combination therapies using Blenrep (belantamab mafodotin) — designed to treat adults with relapsed or refractory multiple myeloma — have been approved in the…
When I wake up in the morning, I do the same things in the same order: Examine the pillbox. Send a text to my mum…